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Abstract
Background: Myxoid liposarcoma (MLS) is a soft tissue sarcoma with adipocytic differentiation characterized by a
unique chromosome rearrangement, t(12;16)(q13;p11). The exact efficacy of chemotherapy in MLS has not been
clearly established.
Patients and methods: We retrospectively analyzed the records of 37 histologically confirmed MLS patients who
were treated at the University of Texas MD Anderson Cancer Center from January 2000 to December 2009 with
doxorubicin 75-90 mg/m
2 over 72 hours combined with ifosfamide 10 gm/m
2 in the first-line setting. Response
was assessed using RECIST and Choi criteria. The Kaplan-Meier method and log-rank test was used to estimate
clinical outcomes.
Results: The median follow-up period was 50.1 months. The overall response rates were 43.2% using RECIST and
86.5% using the Choi criteria. The 5-year disease-free survival rate was 90% for patients with resectable tumors.
Median time to progression and overall survival time for the advanced-disease group were 23 and 31.1 months,
respectively.
Conclusion: Our study demonstrates that doxorubicin-ifosfamide combination therapy has a role in the treatment
of MLS. The Choi criteria may be more sensitive in evaluating response to chemotherapy in MLS.
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Introduction
Liposarcoma is the name given to a group of soft tissue
sarcomas (STSs) with adipocytic differentiation. As a
group, the liposarcomas are the second most common
STS in adults. Approximately half of these tumors are
further sub-classified as myxoid/round cell liposarcomas
(MLSs) based on a multinodular gelatinous appearance
and a unique chromosome rearrangement, t(12;16)(q13;
p11), involving the DDIT3 and FUS genes, respectively.
This chromosome rearrangement or a rare variant in
which FUS is substituted by EWSR1 (22q12) is found in
virtually all MLS cases and supports the diagnosis [1].
MLS exhibits distinct clinical features, such as a propen-
sity to develop in the lower extremity, particularly the
medial thigh or the popliteal area, and only very rarely
in the retroperitoneum as a primary site [2]. Further-
more, compared with other STSs, it has a strong predis-
position to metastasize to nonpulmonary sites such as
the intraperitoneum, the retroperitoneum, or the para-
spinal fat [2-4]. Staging and grading of these tumors are
no different from those of other STSs, with the extent
of the round-cell change/hypercellularity component in
the tumor reflecting aggressiveness [5].
As with other STSs, the cornerstone of successful treat-
ment for localized MLS disease is surgical excision. Radia-
tion is part of the multidisciplinary approach commonly
applied to tumors larger than 5 cm [6]. Chemotherapy is
added for tumors larger than 10 cm and may be used for
selected tumors in the 5- to 10-cm range, and it is the
mainstay treatment of metastatic disease. Doxorubicin and
ifosfamide in combination (AI) are often used as a first-
line regimen in previously untreated patients with STS,
with response rates of 10-66% [7-9]. Earlier studies have
shown that STS response to AI follows a positive dose-
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any medium, provided the original work is properly cited.response curve, with doxorubicin given at doses of 75 mg/
m
2 a n di f o s f a m i d ea t1 0g m / m
2 providing the best effi-
cacy-to-toxicity ratio [10-12]. As a result, this regimen was
adopted a decade ago as the standard of care for first-line
STS patients 65 years and younger at The University of
Texas MD Anderson Cancer Center. Experience acquired
at our institution with this dose-intensive regimen has
been particularly promising for MLS tumors, which have
had a higher response rate than have other STSs. How-
ever, the sarcoma literature is vague on the response rates
of MLS to AI, mainly because studies often report results
with all liposarcoma subtypes pooled [11,13], a disadvan-
tage for MLSs, which appear to be more sensitive than
other liposarcomas to chemotherapy. In support of the
chemotherapy responsiveness of MLS, the few studies that
have addressed the response of MLS alone to different
chemotherapy regimens, such as a doxorubicin-based regi-
men or single-agent trabectedin (Yondelis), demonstrate
an overall response rate of 45-50% [14-16].
The fact that studies have not specifically addressed
the outcome of MLS patients treated with doxorubicin
75 mg/m
2 and ifosfamide 10 gm/m
2 dosing regimen
prompted us to retrospectively evaluate our institutional
experience with first-line AI for chemotherapy-naïve
patients with localized or advanced MLS. Response was
assessed using both Response Evaluation Criteria in
Solid Tumors (RECIST) [17] and Choi criteria [18].
Patients and Methods
Patients
Patients were identified by searching the MD Anderson
computerized database for a diagnosis of MLS between
January 2000 and December 2009. Review of data began
after approval from our institutional review board. We
identified 37 chemotherapy-naïve patients who had
either localized (resectable) or advanced (metastatic or
nonresectable) measurable MLS. These patients were
then treated with up to eight cycles of AI. Demographic
data, tumor characteristics, chemotherapy dosage and
schedule, radiotherapy administration, surgical margin
status, and patient outcome were extracted from clinical
records. Toxicity data (dose reduction, discontinuation
of chemotherapy, and death during treatment) were
gathered. All imaging studies, including computed
tomography (CT) and magnetic resonance imaging
( M R I )s c a n s ,w e r er e v i e w e db yas i n g l eM DA n d e r s o n
radiologist (P.B.). Tissue diagnosis of MLS was con-
firmed in each case independently by two MD Anderson
sarcoma pathologists (A.J.L., W.-L.W.).
Treatment
The 37 patients in this retrospective review were treated
according to the Department of Sarcoma Medical
Oncology’s standard approach for high-grade STSs
larger than 5 cm, which is a combination of chemother-
apy, radiotherapy, and definitive surgery when feasible.
These patients received doxorubicin (75-90 mg/m
2 as a
continuous infusion over 72 hours every 3 weeks) com-
bined with ifosfamide (10 gm/m
2 given in divided doses
of 2.5 gm/m
2 infused over 3 hours daily for 4 days,
every 3 weeks). Radiotherapy was administered either
before or after surgery following the recommendations
of our institution’s sarcoma multidisciplinary team com-
prised of sarcoma surgeons, radiotherapists, radiologists,
and sarcoma medical oncologists. Baseline and follow-
up imaging were performed with CT and/or MRI every
two cycles to assess response.
Endpoints
The primary study endpoint was to assess objective
response to treatment with first-line AI. RECIST [17]
and Choi criteria [18] were used for evaluation of
response. For tumors that were imaged with MRI, the
density response aspect of the Choi criteria were not
evaluable; only the size aspect was used for response
assessment.
Statistical analysis
Fisher’s exact test was used to determine the association
of response and categorical variables, as well as to com-
pare some patient characteristics between the resectable-
and advanced-disease groups. The Wilcoxon rank sum
test was used to compare each of the continuous vari-
ables between patients with PR and patients with stable
disease and between resectable- and advanced-disease
patients. The Kaplan-Meier method and log-rank test
were used to analyze time-to-event variables, including
overall survival and disease-free survival.
Results
Patient characteristics
Corresponding clinical data and imaging were reviewed
for 37 patients. Table 1 summarizes the clinical data. All
patients were chemotherapy-naïve and received AI as
part of their initial treatment. Twenty-six patients
received neoadjuvant AI for localized tumors, and 11
patients received first-line AI for advanced disease (four
presented with metastatic disease, and seven had distant
relapse). The vast majority of primary tumors were
found in the lower extremity, while advanced disease
involved bones, the abdomen, and the upper trunk
(Table 1).
Treatment adherence and safety
All patients treated with neoadjuvant AI for a resectable
tumor received between four and six cycles, with 17 of
26 patients (65%) receiving six cycles and only two
patients receiving four cycles (Table 1). No patient
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administering fewer than six cycles were patient’s prefer-
ence (three patients), maximum tumor response (three
patients), secondary tumor resistance (one patient), and
myelosuppression (two patients). For patients with
advanced disease, between five and eight cycles of AI
were administered. For these patients, AI chemotherapy
was discontinued because of maximum response (seven
patients), progression after the fifth cycle (one patient),
and patient preference to discontinue treatment after
the sixth cycle (one patient). Doxorubicin at an intensi-
fied dose of 90 mg/m
2 was administered to 11 patients
(eight with resectable disease and three with advanced
disease). In general, patients tolerated the AI regimen
well. Only two patients had prolonged myelosuppres-
sion, which led to the discontinuation of chemotherapy
after the fifth cycle. In one patient, the doxorubicin
delivery duration was decreased to 48 hours because of
mucositis. No toxicity-related deaths occurred during
treatment.
Table 1 Patient characteristics.
Characteristic Resectable tumor No.
(%)
Advanced disease No.
(%)
Total No. (%) P
value
Total no. of patients 26 11 37
Sex 0.48
Male 15 (57.7) 3 (27.3) 18 (48.6)
Female 11 (42.3) 8 (72.7) 19 (51.4)
Race 0.35
White 15 (57.7) 10 (90.9) 25 (67.6)
Hispanic 6 (23.0) 1 (9.1) 7 (18.9)
African American 4 (15.4) 0 (0) 4 (10.8)
Asian 1 (3.8) 0 (0) 1 (2.7)
Age in years at the time of treatment, mean ± SD (range) 42.3 ± 12.8 (14-72) 43.8 ± 6.4 (37-55) 42.7 ± 11.4 (14-72) 0.87
Tumor size in cm, median (range) 14.9 (6-23.3)
Disease site
Lower extremity 23 (88.5)
Neck 1 (3.8)
Retroperitoneum 1 (3.8)
Perineum 1 (3.8)
Number of disease sites
Single site (abdominal cavity, bone
a, heart, mediastinum) 5 (45.5)
2 sites
b 5 (45.5)
3 sites
c 1 (9.1)
Tumor side
Left 15 (57.7)
Right 11 (42.3)
Hypercellular round cell tumor 1 (3.8) 1 (9.1) 2 (5.4) 0.82
Chemotherapy
Median no. of chemotherapy cycles, median (range) 6 (4-6) 6 (5-8) 6 (4-8) 0.02
Intensified doxorubicin dose (90 mg/m
2) 8 (30.7) 3 (27.2) 11 (33.3) 1.00
Surgery (R0 intent) 26 (100)
Free margins 21 (80.8)
Positive margins (R1) 5 (19.2)
Radiotherapy
Before surgery 21 (80.8)
After surgery 5 (19.2)
aAll bony involvement is reported as a single site (involved bones: sternum and spine, orbit and rib).
bInvoled sites: lung and sacrum, retroperitoneum and chest wall, sacrum/T5 and peritoneum, sacrum and buttock, mediastinum and tibia (local recurrence).
cInvolved sites: Pelvis, lung and abdominal cavity implants.
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Table 2 summarizes responses determined using the
RECIST and Choi criteria. Patients with resectable dis-
ease and patients with advanced disease did not differ
significantly in response rates to AI (RECIST, p = 0.48;
Choi criteria, p = 1.00). The PR rate for the entire
cohort was 43% (n = 16) by RECIST and 87% (n = 32)
by Choi criteria. The maximum tumor diameter
decreased by an average of 28% (median 26%, range 5-
57%.), and the mean time to maximum response was 4.4
months (median 4 months, range 2-10 months). No
complete responses or disease progressions during preo-
perative treatment were recorded, and all patients with
resectable disease underwent surgery with an R0 (cura-
tive) intent. Median follow-up for the entire group was
50.1 months (95% CI, 34-76.1 months). Six patients who
received preoperative chemotherapy (two with positive
margins) developed distant metastases diagnosed at a
median of 23 months (range, 14-50 months) following
surgery; two of these six patients died. The disease-free
survival rate at 5 years for patients with resectable
tumors was 90% (95% CI, 73.2-100%) (Figure 1). For the
advanced-disease group, median time to progression
(TTP) was 23 months (95% CI, 9.01-NA), and median
overall survival was 31.1 months (95% CI, 20-NA) (Fig-
ure 2).
When Fisher’s exact test was applied, no significant
association was detected for response evaluated by
either RECIST or Choi criteria with age, sex, tumor
size, resectability, primary or advanced disease, round-
cell change/hypercellularity, doxorubicin dose (75 or
90 mg/m
2), or number of cycles of chemotherapy. Of
course, the numbers in any of these subgroups were
very small.
Discussion
Inherently, MLSs are very chemotherapy-responsive
tumors, and this modern series confirms that finding.
T h ed o s e - i n t e n s i v er e g i m e no fd o x o r u b i c i n( 7 5 - 9 0m g /
m
2) and ifosfamide (10 gm/m
2) in this study attained a
PR rate of 43.2% by RECIST and 86.5% by Choi criteria
for the entire cohort. No patient had progressive disease
as the initial response to therapy. The efficacy of this
regimen was not statistically different between patients
with resectable disease and patients with advanced dis-
ease. We were encouraged by the high response rate,
accompanied by a lack of disease progression, observed
during the first four to six cycles, which highlights the
utility of chemotherapy in the preoperative setting, in
which chemotherapy is likely to shrink the tumor or kill
tumor cells.
The high efficacy of dose-intensive AI in MLS appears
to be not a feature unique to this regimen but rather a
feature of the chemotherapy sensitivity of MLS. Patel et
al. [16] reported a response rate of 44% (by RECIST) in
18 patients treated with first-line doxorubicin (60-90
mg/m
2 as a 48- to 96-hour continuous infusion) and
dacarbazine (900-1000 mg/m
2) with or without cyclo-
phosphamide (600-750 mg/m
2). Grosso et al. [15]
reported a high response rate of 51% per RECIST in a
retrospective study of patients treated with trabectedin
and noted that a substantial number of these patients
( 7 4 % )d e m o n s t r a t e dw h a tt h e i rg r o u pt e r m e dt i s s u e
response prior to tumor shrinkage. These tissue
responses would all qualify as Choi responses. Similar
response rates were recently reported in a prospective
study by Gronchi et al. [14]. In that phase II study, 13
patients were treated preoperatively with first-line tra-
bectedin (1.5 mg/m
2 every 3 weeks) and had a 46%
Table 2 Efficacy of AI and clinical outcome
Resectable tumor No.
(%)
Advanced disease No.
(%)
Total No. (%) P value
Response by RECIST 0.48
PR 10 (38.5) 6 (54.5) 16 (43.2%)
SD 16 (61.5) 5 (45.5) 21 (56.8%)
Response by Choi criteria 1.00
PR 22 (84.6) 10 (91) 32 (86.5%)
SD 4 (15.4) 1 (9) 5 (13.5%)
Maximum % decrease in tumor size in cm, median
(range)
26.3 (6.2-56.1) 29.9 (4.5-56.8) 27.6% (4.5-
56.8)
0.5
Time to maximal response in months, median (range) 4 (2-10) 4 (3-7) 4 (1.9-10.1) 0.44
5-years DFS 90% (95% CI, 73.2 to
100)
TTP in months, median 23 (95% CI, 9.01 to
NA)
OS in months, median 31.1 (95% CI, 20 to NA)
Abbreviations: PR partial response, SD stable disease, DFS disease-free survival,
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during the neoadjuvant period.
In addition to being chemotherapy sensitive, MLSs are
also quite radiotherapy sensitive, as demonstrated by
Guadagnolo et al. [19]. In their study, radiotherapy
given before or after surgery to 128 MLS patients
resulted in a 97% 5-year local control rate, accompanied
by an 81% 5-year disease-free survival rate and 87%
overall survival rate. The high efficacy of chemotherapy
and radiotherapy in MLS suggests they should play a
role whenever surgical morbidity or organ functionality
preservation issues arise in the neoadjuvant setting.
Based on the definitions of the Choi criteria, it is not a
surprise that their use results in a significantly higher
Figure 1 Disease-free survival in patients with resectable tumors (Neo) and in patients with advanced disease (Met).
Figure 2 Overall survival in patients with resectable tumors (Neo) and in patients with advanced disease (Met).
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set the bar for PR lower, identifying PR as a 10%
decrease in tumor size, compared with 30% using
RECIST. Bearing this difference in mind from a clinical
perspective, Choi criteria better mirror day-to-day prac-
tice in the clinic, where decisions about chemotherapy
continuation often need to be made based on subtle
changes in tumor size. However, the major caveats for
the Choi criteria seem to be twofold: First, although the
method has been validated in assessing responses in gas-
trointestinal stromal tumors treated with imatinib mesy-
late [17], it is not yet widely accepted nor utilized for
monitoring responses to chemotherapy in other tumor
types. However, we believe that monitoring and report-
ing responses by both RECIST and Choi criteria, as was
done in this study, is more informative than RECIST
a l o n eb e c a u s et h eC h o ic r i t e r i ac a p t u r em o r es u b t l e
changes in tumor response and provide a more accurate
assessment for oncologists and their patients regarding
the probability of benefit from chemotherapy.
The second caveat for the Choi criteria is that for
determining density, a CT scan with contrast is
required. This aspect of the Choi criteria is less amen-
able to primary MLS since the majority of tumors origi-
nate in an extremity, where MRI is often the preferred
imaging modality. Nevertheless, since changes in tumor
size may be insufficient to represent actual tumor
response, Stacchiotti et al. [20] suggested MRI with con-
trast material enhancement to complement tumor size,
thus making Choi criteria a predictive tool of pathologic
response in high-grade STS. Interestingly, decreased
contrast enhancement, either on CT or MRI, following
chemotherapy appears to be a predictor of pathological
response.
The current study was limited by its retrospective
nature that precluded strict follow-up as well as toxi-
city monitoring. Nevertheless, from our long-standing
experience with this dose-intensive regimen, its toxicity
is manageable and involves mostly myelosuppression;
only two patients out of 37 in our study had to discon-
tinue treatment, and in both cases discontinuation was
secondary to prolonged myelosuppression. Severe
potential forms of toxicity related to this regimen,
such as cardiotoxicity, nephrotoxicity, and neurotoxo-
city, are relatively rare in our sarcoma center due to
stringent follow-up and the employment of a series of
preventive measures, such as the use of continuous-
infusion doxorubicin treatment over 72-96 hours or
bolus administration with dexrazoxane (Zinecard) in
lieu of bolus doxorubicin alone; generous hydration
combined with forced diuresis when needed; monitor-
ing of fluid status and creatinine levels on a daily
basis; and supplementing with bicarbonate and electro-
l y t e ss u c ha sp o t a s s i u m ,m a g n e s i u m ,a n dp h o s p h o r u s .
Finally, setting a serum albumin lower limit of 3 gm/dl
for initiating treatment with ifosfamide and supple-
menting with intravenous albumin significantly
decrease neurotoxicity. In addition to the regimen-
related preventive measures above, routine supportive
care, including antibiotics, antiemetics, and growth fac-
tors, is also provided to all patients.
This study was also limited by the small number of
patients, which precluded further analysis for any asso-
ciation between response and other variables such as
age, sex, round-cell change/hypercellularity, doxorubicin
dose (75 or 90 mg/m
2), or number of cycles.
To our knowledge, this is the first report describing
response to first-line AI in MLS. By reporting responses
by both RECIST and Choi criteria, we were able to
compare our findings with other studies that used the
more conventional RECIST alone. We conclude that
MLS is a chemotherapy-responsive tumor and that AI
dose-intensive chemotherapy is an effective and safe
approach for MLS. We advocate the use of more sensi-
tive criteria such as the Choi criteria in evaluating
response to chemotherapy.
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